Syros Pharmaceuticals, Inc.
Syros Pharmaceuticals, Inc. (SYRS): 4 pipeline candidates · ~9 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
8.9 months
47% dilution
Lead: Phase 2
4 candidates
N/A
N/A
A transparent, data-derived signal for Syros Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$3K
Cash
$60.4M
Quarterly Burn
$20.7M
Runway
8.9 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| sy-12882 | Preclinical |
| sy-2101 | Phase 1 |
| sy-5609 | Phase 1 |
| tamibarotene | Phase 2 |
Frequently asked questions
How many drug candidates are in Syros Pharmaceuticals, Inc.'s pipeline?
Syros Pharmaceuticals, Inc. (SYRS) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Syros Pharmaceuticals, Inc.'s lead drug candidate?
Syros Pharmaceuticals, Inc.'s most advanced tracked candidate is sy-12882 (Preclinical) for Oncology.
What is Syros Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Syros Pharmaceuticals, Inc. has approximately 8.9 months of cash runway.
What is Syros Pharmaceuticals, Inc.'s market capitalization?
Syros Pharmaceuticals, Inc.'s market capitalization is approximately $3K.
Who is the CEO of Syros Pharmaceuticals, Inc.?
Massachusetts April is the chief executive officer of Syros Pharmaceuticals, Inc. (SYRS).
Get the full picture on Syros Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.